Stocks New York Times Co

More

  • LISBON, Oct 30- Portuguese prosecutors have asked for Canadian academic Peter Boone to be put on trial after he wrote articles predicting a debt crisis in Portugal similar to Greece's and then, they say, made nearly $1 million from price moves in that market. The Lisbon District Prosecutor's Office said that after a long investigation it had decided to ask for...

  • LONDON, Oct 30- Britain's biggest-selling newspaper the Sun is to take down its online paywall, after the Rupert Murdoch-owned tabloid failed to win enough readers in the latest troubled digital experiment for a traditional publisher. The decision to remove the paywall is also the first strategic change from Rebekah Brooks since she returned to oversee the...

  • Oct 29- New York Times Co reported a higher-than-expected quarterly profit, and said it expected digital revenue from its international business to account for a significant portion of its revenue in five years. "International revenue should be a significant part of our $800 million target," Chief Executive Mark Thompson told Reuters on Thursday.

  • Oct 29- New York Times Co said it expected a "significant part" of its targeted $800 million annual digital revenue by 2020 to come from outside the United States. "We've got ourselves a 5 year target of $800 and I expect a significant part of that to come from outside the U.S. and I think it will be a blend of digital subscription and digital advertising revenue...

  • Oct 29- New York Times Co reported a higher-than-expected quarterly profit after its cost-cutting initiatives paid off. Net income attributable to shareholders from continuing operations was $9.4 million, or 6 cents per share, in the third quarter, compared with a loss of $12.5 million, or 8 cents per share, a year earlier. Excluding items, the company earned 9...

  • New York Times reports better-than-expected profit Thursday, 29 Oct 2015 | 8:46 AM ET

    Oct 29- New York Times Co reported a higher-than-expected quarterly profit as its cost-cutting initiatives paid off. Net income attributable to shareholders from continuing operations was $9.4 million, or 6 cents per share, in the third quarter, compared with a loss of $12.5 million, or 8 cents per share, a year earlier. Excluding items, the company earned 9 cents...

  • Oct 27- The U.S. Federal Trade Commission is looking into whether Canadian drugmaker Valeant Pharmaceuticals International Inc illegally cornered the market for a component of a new type of contact lens, an industry source told Reuters. Valeant said on Monday it had received a letter from the FTC on or about Oct. 16 seeking more information about Valeant's...

  • Oct 27- The U.S. Federal Trade Commission is looking into whether Canadian drugmaker Valeant Pharmaceuticals International Inc illegally cornered the market for a key material used to make rigid contact lenses, ProPublica reported, citing people familiar with the matter. The New York Times also reported last week that Valeant and other drugmakers were...

  • Oct 26- U.S. federal prosecutors are preparing to announce criminal charges against a former Goldman Sachs banker alleged to have obtained confidential documents from the Federal Reserve Bank of New York, a person familiar with matter said on Monday. Separately, the New York Department of Financial Services is looking at fining Goldman Sachs $50 million and...

  • Oct 26- Drugmaker Valeant Pharmaceuticals International Inc laid out a detailed defense on Monday of its relationship with a little-known specialty pharmacy, but its arguments failed to calm all investors' concerns. Valeant's shares were little changed in New York and Toronto around midday, in choppy trading after tumbling as much as 14 percent before...

  • Oct 26- U.S. federal prosecutors are planning to announce a criminal case this week against a former Goldman Sachs Group Inc banker suspected of taking confidential documents from a government employee, the New York Times reported. When Bansal joined Goldman in July 2014, he was assigned to advise one of the same banks he had previously regulated when he worked...

  • UPDATE 3-Drugmaker Valeant raises detailed defense Monday, 26 Oct 2015 | 10:46 AM ET

    Oct 26- Drugmaker Valeant Pharmaceuticals International Inc laid out a detailed defense on Monday of its relationship with a little-known specialty pharmacy, but its arguments failed to calm all investors' concerns. Valeant's shares were up about 1 percent in New York and Toronto after tumbling as much as 14 percent before normal trading hours.

  • Oct 26- Drugmaker Valeant Pharmaceuticals International Inc said on Monday it has asked U.S. securities regulators to investigate a short-seller's "completely untrue" allegation that the company used its ties with a specialty pharmacy to inflate revenue, and said it would conduct a review of its pharmacy network. Laval, Quebec- based Valeant fired back in a...

  • Oct 26- Valeant Pharmaceuticals International Inc said on Monday it would set up an ad hoc committee to look into allegations related to the company's association with specialty pharmacy distributor Philidor. Valeant's link to Philidor and its option to buy the company came under scrutiny after a New York Times report said that Valeant and other drugmakers...

  • Oct 26- Canadian drugmaker Valeant Pharmaceuticals International Inc said on Monday it would set up an ad hoc committee to look into allegations about the company's association with specialty pharmacy distributor Philidor. The company's link to the drug distributor and its option to buy Philidor came under scrutiny after a New York Times report said that...

  • Fed could be a snooze, but these reports will be big Friday, 23 Oct 2015 | 4:52 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Expectations are low that the Fed will provide any new policy insight next week, and focus should stay on economic reports and a flood of earnings.

  • TORONTO/ NEW YORK, Oct 22- Valeant Pharmaceuticals International Inc moved to reassure investors on Thursday after being accused of using specialty pharmacies to inflate revenue, and said it would refute them in detail on a conference call with investors. Valeant said at least 10 of its executives and board members would participate in a call on Monday,...

  • LOS ANGELES, Oct 21- Investor concerns over accounting practices at Valeant Pharmaceuticals International Inc have put a spotlight on the little-known and fast-growing specialty pharmacy industry. Shares of Valeant fell 19 percent on Wednesday after influential short-seller Citron Research accused the company of using specialty pharmacies, through a...

  • Allergan clarifies on drug distribution practices Wednesday, 21 Oct 2015 | 12:20 PM ET

    Oct 21- Drugmaker Allergan Plc said on Wednesday that nearly all of its drugs are being distributed through traditional wholesale and retail channels. Allergan's clarification comes two days after a New York Times report said drugmakers were using specialty pharmacy distributors to work around barriers to increase drug prices. The company also said on...

  • UPDATE 1-Valeant shares plunge on short-seller report Wednesday, 21 Oct 2015 | 11:07 AM ET

    Oct 21- Shares of Valeant Pharmaceuticals International Inc plunged 30 percent after a short-seller released a report accusing the company of fraud. Valeant has been under fire for its drug pricing practices, and last week disclosed that its pricing practices and patient assistance programs were under investigation by federal prosecutors in New York and...